Immuneering (IMRX) Capital Expenditures (2020 - 2026)
Immuneering (IMRX) posted quarterly Capital Expenditures of $79930.0 for Q1 2026, up 793.57% year-over-year from $8945.0 in Q1 2025, and down 35.49% quarter-over-quarter from $123910.0 in Q4 2025.
Immuneering (IMRX) Capital Expenditures (2020 - 2026) Analysis & Trends
Immuneering's Capital Expenditures history runs 7 years deep, the most recent figure standing at $79930.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 793.57% year-over-year to $79930.0; the TTM figure through Mar 2026 stood at $213211.0 (up 278.42% YoY), while the FY2025 annual figure was $142226.0, up 67.57% from the prior year.
- Capital Expenditures for Q1 2026 stood at $79930.0, down from $123910.0 in the prior quarter.
- The five-year high for Capital Expenditures was $393134.0 in Q3 2022, with the low at $2116.0 in Q2 2025.
- The 5-year median for Capital Expenditures is $57149.0 (2023), against an average of $81897.6.
- The sharpest annual moves came in 2022 and 2024: Capital Expenditures soared 3364.96% in 2022, then sank 94.53% in 2024.
- Immuneering's Capital Expenditures stood at $69302.0 in 2022, then soared by 146.63% to $170918.0 in 2023, then tumbled by 94.53% to $9356.0 in 2024, then jumped by 1224.39% to $123910.0 in 2025, then tumbled by 35.49% to $79930.0 in 2026.
- Business Quant data shows IMRX's Capital Expenditures at $79930.0 in Q1 2026, $123910.0 in Q4 2025, and $7255.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 27,367.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27,367.00 |
| Jun 30, 2026 | 27,367.00 |
| Mar 31, 2026 | 79,930.00 |
| Mar 31, 2026 | 79,930.00 |
| Dec 31, 2025 | 123,910.00 |
| Dec 31, 2025 | 123,910.00 |
| Sep 30, 2025 | 7,255.00 |
| Sep 30, 2025 | 7,255.00 |
| Jun 30, 2025 | 2,116.00 |
| Jun 30, 2025 | 2,116.00 |
| Mar 31, 2025 | 8,945.00 |
| Mar 31, 2025 | 8,945.00 |
| Dec 31, 2024 | 9,356.00 |
| Dec 31, 2024 | 9,356.00 |
| Sep 30, 2024 | 5,268.00 |
| Sep 30, 2024 | 5,268.00 |
| Jun 30, 2024 | 32,773.00 |
| Jun 30, 2024 | 32,773.00 |
| Mar 31, 2024 | 37,478.00 |
| Mar 31, 2024 | 37,478.00 |